Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
- Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah.
- A poster presentation showed that paxalisib is active in vitro and in vivo against a range of preclinical models of metastatic melanoma, the most aggressive form of skin cancer.
- The data suggested substantial activity for paxalisib as monotherapy and greater activity in combination with MEK and BRAF inhibitors, commonly used two classes of drugs for melanoma patients.
- Kazia anticipates further data from the ongoing collaboration with the Huntsman Cancer Institute in CY2023. Depending on the results, Kazia may evaluate future opportunities to launch a clinical trial of paxalisib in melanoma.
- A broad clinical program exploring paxalisib in multiple forms of brain cancer is ongoing. In 2022, two ongoing clinical trials of paxalisib in treating brain metastases have reported positive interim results and graduated to expansion cohorts.
- In addition, six other clinical trials of paxalisib in other forms of adult and pediatric brain cancer are ongoing, with multiple data read-outs anticipated throughout CY2023.
- Price Action: KZIA shares are down 3.94% at $0.98 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Preclinical PhaseBiotech News Penny Stocks Health Care General
